The earnings call reflects a positive outlook for Exagen, marked by record revenue growth, successful biomarker launches, and strategic leadership additions. While there are challenges related to operating losses and increased expenses, the company's strong cash position and positive revenue guidance indicate resilience and growth potential.

Company Guidance

During the Exagen Inc. Q2 2025 earnings call, the company reported record revenue of $17.2 million, marking a 14% year-over-year growth. The AVISE CTD test saw substantial volume growth, with an average revenue per territory of over $430,000, a significant increase from $285,000 per territory a few years prior. The company's strategy focuses on organic growth driven by existing commercial teams and the clinical recognition of its differentiated science. Exagen maintained 40 territories as of Q2, but anticipates further expansion to potentially 45 by year-end. The call highlighted ongoing improvements in revenue cycle efforts and consistent ordering patterns from high-value clinicians. Additionally, the company launched novel biomarkers that have been well-received by clinicians, contributing to increased ASP, which grew by $27 year-over-year to $428. Exagen also ended the quarter with over $30 million in cash and equivalents, positioning itself for a path to profitability, with full-year revenue guidance of $65 million to $70 million.

Record Revenue Achieved

Exagen reported Q2 revenue of $17.2 million, marking a 14% year-over-year growth and the highest quarterly revenue in company history.

Significant Per Territory Revenue Growth

Average revenue per territory reached over $430,000, a 50% increase from two years ago, reflecting strong commercial leverage.

Successful Biomarker Launch

The launch of novel T cell and RA markers has significantly enhanced commercial discussions and clinical adoption.

Expansion of R&D and Leadership

Exagen made two significant hires: Dr. Michael Mahler as Chief Scientific Officer and Chas McKhann to the Board of Directors, enhancing the company's scientific credibility and strategic direction.

Strong Cash Position

The company ended the quarter with over $30 million in cash and equivalents, with a path towards neutral operating cash flow.

Positive Revenue Guidance

Exagen provided a full-year revenue guidance of between $65 million and $70 million, with expectations of positive adjusted EBITDA in Q4.

Exagen (XGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.16 / -	-0.28	―	―	―
Jul 29, 2025	2025 (Q2)	-0.15 / -0.21	-0.16	-31.25% (-0.05)	―
May 05, 2025	2025 (Q1)	-0.20 / -0.20	-0.19	-5.26% (-0.01)	―
Mar 11, 2025	2024 (Q4)	-0.26 / -0.20	-0.31	35.48% (+0.11)	―
Nov 12, 2024	2024 (Q3)	-0.29 / -0.28	-0.31	9.68% (+0.03)	―
Aug 05, 2024	2024 (Q2)	-0.34 / -0.16	-0.28	42.86% (+0.12)	―
May 13, 2024	2024 (Q1)	-0.36 / -0.19	-0.44	56.82% (+0.25)	―
Mar 18, 2024	2023 (Q4)	-0.43 / -0.31	-0.83	62.65% (+0.52)	―
Nov 13, 2023	2023 (Q3)	-0.47 / -0.31	-0.47	34.04% (+0.16)	―
Aug 07, 2023	2023 (Q2)	-0.50 / -0.28	-0.78	64.10% (+0.50)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$7.39	$8.45	+14.34%
May 05, 2025	$6.02	$6.25	+3.82%
Mar 11, 2025	$2.85	$3.37	+18.25%
Nov 12, 2024	$2.97	$2.79	-6.06%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exagen Inc (XGN) report earnings?

Exagen Inc (XGN) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is Exagen Inc (XGN) earnings time?

Exagen Inc (XGN) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XGN EPS forecast?

XGN EPS forecast for the fiscal quarter 2025 (Q3) is -0.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing